BNP Paribas Financial Markets Purchases Shares of 96,433 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

BNP Paribas Financial Markets acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 96,433 shares of the company's stock, valued at approximately $323,000. BNP Paribas Financial Markets owned 0.11% of Atea Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. BML Capital Management LLC raised its stake in shares of Atea Pharmaceuticals by 14.4% in the fourth quarter. BML Capital Management LLC now owns 7,608,312 shares of the company's stock worth $25,488,000 after buying an additional 958,312 shares during the period. Renaissance Technologies LLC raised its stake in shares of Atea Pharmaceuticals by 0.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,216,600 shares of the company's stock worth $4,076,000 after buying an additional 9,500 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Atea Pharmaceuticals by 23.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 977,470 shares of the company's stock worth $3,274,000 after buying an additional 183,844 shares during the period. Northern Trust Corp raised its stake in shares of Atea Pharmaceuticals by 2.5% in the fourth quarter. Northern Trust Corp now owns 704,909 shares of the company's stock worth $2,361,000 after buying an additional 17,471 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Atea Pharmaceuticals by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company's stock worth $2,209,000 after buying an additional 9,370 shares during the period. Institutional investors own 86.67% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on AVIR shares. Morgan Stanley decreased their price objective on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. William Blair reiterated an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday, March 7th. Finally, Wall Street Zen upgraded Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd.

Atea Pharmaceuticals Price Performance

Shares of NASDAQ:AVIR traded up $0.03 during trading on Friday, hitting $2.98. 570,319 shares of the company's stock were exchanged, compared to its average volume of 311,575. Atea Pharmaceuticals, Inc. has a 52-week low of $2.46 and a 52-week high of $4.15. The business's 50-day simple moving average is $2.86 and its 200 day simple moving average is $3.06. The company has a market cap of $255.03 million, a price-to-earnings ratio of -1.44 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.16. On average, sell-side analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.